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Mesenchymal stem cells (MSCs) (also known as multipotent mesenchymal stromal cells) possess the capacity for
self-renewal and multi-lineage differentiation, and their ability to enhance cutaneous wound healing has been well
characterized. Acting via paracrine interactions, MSCs accelerate wound closure, increase angiogenesis, promote
resolution of wound inflammation, favorably regulate extracellular matrix remodeling, and encourage regeneration
of skin with normal architecture and function. A number of studies have employed novel methods to amplify the
delivery and efficacy of MSCs. Non-traditional sources of MSCs, including Wharton’s jelly and medical waste
material, have shown efficacy comparable to that of traditional sources, such as bone marrow and adipose tissue.
The potential of alternative methods to both introduce MSCs into wounds and increase migration of MSCs into wound
areas has also been demonstrated. Taking advantage of the associations between MSCs with M2 macrophages
and microRNA, methods to enhance the immunomodulatory capacity of MSCs have shown success. New
measures to enhance angiogenic capabilities have also exhibited effectiveness, often demonstrated by
increased levels of proangiogenic vascular endothelial growth factor. Finally, hypoxia has been shown to have
strong wound-healing potential in terms of increasing MSC efficacy. We have critically reviewed the results of
the novel studies that show promise for the continued development of MSC-based wound-healing therapies
and provide direction for continued research in this field.Background
Mesenchymal stem cells (MSCs) are characterized by
the ability to self-renew and exhibit differentiation into
multiple tissue-forming cell lineages, such as osteoblasts,
adipocytes, chondrocytes, tenocytes, and myocytes [1].
Obtainable from a number of tissues, including bone
marrow, adipose tissue, and the umbilical cord, MSCs
are also characterized by the expression of surface CD
markers, including CD44+, CD73+, CD90+, and CD105+,
and are distinguished from hematopoietic cells by a lack
of CD34, CD45, CD14, and HLA-DR [1]. MSCs have
also been shown to exhibit immunomodulatory, repara-
tive, and regenerative effects through paracrine signaling,
suggesting great therapeutic potential [2, 3].
Wound healing is a complex process requiring cell mi-
gration, inflammation, angiogenesis, granulation tissue* Correspondence: dkagr@creighton.edu
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(ECM) remodeling. MSCs have an active role through
this process, and therapeutic application of MSCs has
been shown to enhance and improve wound-healing
outcomes. Here, we critically reviewed the ability of
MSCs to enhance cutaneous wound healing and dis-
cussed the novel methods used to increase MSC delivery
and efficacy.Mesenchymal stem cells enhance wound healing
By accelerating wound closure, enhancing re-
epithelialization, increasing angiogenesis, promoting
granulation tissue formation, modulating inflammation,
and regulating ECM remodeling, administration of
MSCs has demonstrated a beneficial effect on cutaneous
wound healing and skin regeneration (Fig. 1). Import-
antly, this beneficial effect appears to be mediated by
paracrine signaling [2, 3].distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Enhanced cutaneous wound healing by mesenchymal stem cells. This involves accelerating wound closure, increasing angiogenesis, decreasing
wound inflammation, positively regulating extracellular matrix (ECM) remodeling, and promoting regeneration of normal skin architecture and
functioning. These effects are mediated via paracrine signaling. GPx glutathione peroxidase, HaCaT immortalized human keratinocyte, HGF hepatocyte
growth factor, ICAM1 intercellular adhesion molecule 1, IL-1 interleukin-1, MMP-1 matrix metalloproteinase-1, SOD superoxide dismutase, TNF-α tumor
necrosis factor-alpha, VEGF vascular endothelial growth factor
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Multiple studies have shown that MSCs enhance wound
healing by accelerating wound closure [4–13]. Walter
et al. [4] demonstrated that human bone marrow-derived
MSCs increased wound closure rate by increasing the
in vitro migration of fibroblasts and keratinocytes. Similar
findings were reported by Smith et al. [5], who found that
the accelerated wound closure in the presence of murine
bone marrow-derived MSCs was due to increased dermal
fibroblast migration, and Jeon et al. [6], who demonstrated
that human skin fibroblasts cultured with human umbil-
ical cord blood MSC-conditioned media exhibited signifi-
cantly elevated migratory ability.
Angiogenesis
MSCs enhance angiogenesis during the wound-healing
process. For example, treatment of rat wound with hu-
man umbilical cord MSCs increases the levels of vascu-
lar endothelial growth factor (VEGF) (one of the most
potent pro-angiogenic factors), the density of microves-
sels, and cutaneous wound microcirculation [8]. Data
from a study of rat adipose-derived stem cells implanted
into rat wounds suggested that the MSCs could partici-
pate in vasculogenesis of wound healing through direct
differentiation into vascular endothelial cells [12], a find-
ing consistent with other studies [14, 15]. These sameMSCs also secreted significantly higher levels of the pro-
angiogenic cytokines VEGF and hepatocyte growth
factor [12]. In another study, Schlosser et al. [3] demon-
strated that injected murine bone marrow MSCs re-
duced arteriolar vascular resistance and increased
functional capillary density in the vasculature of murine
skin recovering from ischemia. The key finding in this
study was the expression of pro-angiogenic cytokines
such as VEGF by the MSCs.
Immunomodulation
Resolution of inflammation is essential to successful
wound healing, and chronic inflammation can lead to
poor healing outcomes [16]. The ability of MSCs to
modulate the inflammatory response in wounds sup-
ports their favorable effect on the healing response. Cu-
taneous rat wounds transplanted with human umbilical
cord MSCs demonstrated a significantly lower number
of inflammatory cells and pro-inflammatory cytokines
such as interleukin (IL)-1 and tumor necrosis factor-
alpha (TNF-α) [8]. Importantly, these wounds also ex-
hibited a shorter recovery time and faster healing rate.
Smith et al. [5] demonstrated that human dermal fibro-
blasts co-cultured with murine bone marrow-derived
MSCs had decreased mRNA levels of intercellular
adhesion molecule 1 (ICAM1). Because it has been
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to dermal fibroblasts, indicating a role in inflammation,
downregulation of ICAM1 expression by these fibro-
blasts may be necessary for resolution of inflammation
during wound repair [17]. A study by Jeon et al. [6]
evaluating the antioxidant activity of fibroblasts exposed
to human umbilical cord MSC-conditioned media dem-
onstrated that the conditioned media significantly pro-
moted superoxide dismutase and glutathione peroxidase
(GPx) synthesis. This detoxifying ability is significant as
superoxide detoxification at wound sites promotes
proper wound healing [18]. Moreover, GPx-mediated de-
toxification of hydrogen peroxide has been shown to be
important for upregulation of VEGF in skin wounds,
suggesting a pro-angiogenic effect [6].
Extracellular matrix remodeling
MSCs have also exhibited an ability to enhance proper
ECM events during the healing process [2, 6, 19]. Condi-
tioned media from human umbilical cord blood MSCs
have been shown to inhibit the expression of matrix me-
talloproteinase (MMP)-1, which suggests that MSCs
suppress degradation of collagenous matrix and serve to
preserve the matrix and contribute to fibroblast regener-
ation [6]. In the same study, this media also significantly
increased the production of collagen and elastin by fi-
broblasts, further suggesting an enhancement of wound
healing. Using human adipose-derived MSCs and an
in vitro wound-healing assay, Lee et al. [2] demonstrated
that treatment with MSCs significantly increased the
proliferation of HaCaT (immortalized human keratino-
cyte) cells and dermal fibroblasts and increased overall
wound healing. These MSCs also enhanced the ability of
dermal fibroblasts to contract collagen lattices, implying
that the MSCs induce fibroblasts to transform into
myofibroblasts.
Skin regeneration
The optimal outcome of cutaneous wound healing in-
volves regeneration of the normal architecture and func-
tion of the skin. Several studies have shown that MSCs
are capable of such regenerative capacity [12, 17, 19, 20].
Luo et al. [20], examining the effect of human umbilical
cord blood MSCs on severe combined immunodeficient
(SCID) mice, reported that, in addition to significantly
enhancing wound-healing rate, MSCs increased the
thickness of the regenerated epidermis, increased the
dermal ridges and amount of cells in regenerated skin,
and produced healing tissue with more regular align-
ment of fibers. Additionally, the MSC-treated wounds
developed hair follicles, sweat glands, and other normal
skin appendages. These results suggest that the adminis-
tration of MSCs not only may be able to accelerate
wound healing but also could enhance wound-healingquality and the physiological functioning of the regener-
ated skin. Another study using an in vitro human
keratinocyte-MSC skin model demonstrated that skin
models in which keratinocytes were cultured with MSCs
gave rise to a multi-layered, well-differentiated epidermis
[19]. These models also expressed collagen, indicating
the ability of MSCs to regulate ECM production.
Novel methods to increase mesenchymal stem cell
delivery and efficacy
The strong therapeutic potential of MSCs in cutaneous
wound healing has led to efforts to determine the opti-
mal sources and delivery methods for MSCs. Recent
studies have also evaluated the ability of novel methods
to maximize the migratory, immunomodulatory, angio-
genic, and reparative abilities of MSCs (Table 1).
Sources for mesenchymal stem cells
Although bone marrow and adipose tissue have proven
to be sources for effective MSCs, several disadvantages
exist, especially for bone marrow MSCs. These include
availability, ethical concerns, and invasive and painful
procedures required for obtainment [21]. As a result, al-
ternative sources for MSCs have been considered and
analyzed (Fig. 2). A study by Arno et al. [22] found that
Wharton’s jelly-derived MSCs, which had not yet been
studied in the context of human skin, caused normal hu-
man skin fibroblasts to coapt wound borders faster
in vitro. More significantly, mice treated with these
MSCs showed increased wound-healing rates, increased
re-epithelialization, and more organized ECM, suggest-
ing that Wharton’s jelly-derived MSCs promoted wound
healing in vivo. In addition, these MSCs upregulated
gene expression of wound-healing factors, including
transforming growth factor-beta (TGF-β), hypoxia-
inducible factor-1α, and plasminogen activator inhibitor-
1. Azari et al. [23] similarly found that Wharton’s jelly
MSCs from caprine umbilical cords enhanced re-
epithelialization of caprine cutaneous wounds. Treated
wounds also exhibited less inflammatory cell infiltration.
MSCs obtained from medical waste material provide a
number of advantages, including abundant availability
and general absence of ethical concerns. The effect of
human placenta-derived MSCs on the wound-healing
rate was evaluated in diabetic Goto-Kakizaki rats, and it
was found that placenta-derived MSC treatment resulted
in significantly smaller wounds with increased collagen
deposition, thicker granulation tissue, thicker epidermal
layers, more regular alignment of fibers, and greater
neovasculariztion [21]. These results demonstrated for
the first time that placenta-derived MSCs, which are
readily available from maternity wards, remarkably in-
creased wound-healing rates. In another study, adipose-
derived MSCs from the hypodermis of discarded skin
Table 1 Summary of the key findings on the therapeutic effects of MSCs
Therapeutic effect on MSCs Method/finding Source of MSCs Wound-healing model Reference
Increased delivery Three-dimensional collagen allograft Rat bone marrow Rat [29]
Microsphere-based engineered skin loaded with EGF Mouse bone marrow Mouse [31]
Increased migration CXCL12/CXCR4 axis Mouse bone marrow Mouse [32]
Platelet-rich plasma Human amniotic fluid Human [34]
EMPB Mouse Mouse [35]
Increased survival Biomimetic pullulan-based hydrogel Mouse Mouse [36]
Increased immunomodulation Polarization of macrophages to M2 phenotype Human gingival tissue Mouse [37]
Increased miRNA-146a Mouse bone marrow Mouse [16]
MSC-derived TSG-6 Human bone marrow Mouse [42]
Increased angiogenesis Biomimetic hydrogel scaffold Mouse bone marrow Mouse [43]
LLLT Dog adipose tissue Mouse [44]
14S,21R-diHDHA Mouse Mouse [45]
v-myc introduction Human adipose tissue Mouse [47]
Increased wound-healing efficacy Hypoxia Human amniotic fluid Mouse [49]
Hypoxia Human adipose tissue Mouse [50]
Hypoxia Human bone marrow Mouse [51]
14S,21R-diHDHA 14S,21R-dihydroxydocosa-4Z,7Z,10Z,12E,16Z,19Z-hexaenoic acid, EGF epidermal growth factor, EMPB Mallotus philippinensis bark, LLLT low-level
laser therapy, miRNA microRNA, MSC mesenchymal stem cell, TSG-6 tumor necrosis factor-alpha-stimulated protein 6
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strated to maintain their stemness and were postulated
to have contributed significantly to the wound healing
and regenerative process [24].
The efficacy of MSCs from different sources appears
to vary, and comparisons have accordingly been per-
formed. A study by Hsieh et al. [25] comparing the an-
giogenic capabilities of Wharton’s jelly MSCs and bone
marrow MSCs found that more human microvascular
endothelial cells moved toward Wharton’s jelly MSCs
compared with bone marrow MSCs. The total vessel
length generated by these cells was also longer when in-
cubated with Wharton’s jelly MSC-conditioned medium
compared with bone marrow MSC-conditioned medium.Mesenchymal
Bone marrow Adipose tissue
Fig. 2 Sources of mesenchymal stem cells. Mesenchymal stem cells can be
tissue, the umbilical cord, Wharton’s jelly, and the placentaEvaluating diabetic murine skin wounds, Kim et al. [13]
determined that, compared with human adipose-derived
MSCs, human amniotic MSCs significantly increased the
rate of fibroblast wound closure. These wounds also dis-
played enhanced re-epithelialization compared with
wounds treated with adipose-derived MSCs. Contrasting
results were seen by Liu et al. [26], who reported that
human adipose MSCs, compared with human amnion
MSCs and human bone marrow MSCs, had the most
pronounced effect on murine wound closure and were
associated with the greatest re-epithelialization and
thickest granulation tissue. The adipose-derived MSCs
also had the greatest effect on human dermal fibroblast




obtained from various sources, including bone marrow, adipose
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higher expression of VEGF, basic fibroblast growth fac-
tor (bFGF), and TGF-β. The discrepancy between these
results suggests a need for future investigation into
which source provides MSCs that exhibit the greater im-
provement in wound healing and therapeutic efficacy.
Delivery methods
Traditionally, most studies have used the technique of
injecting MSCs intradermally into or around the wound
area. Although this method has been shown to improve
wound healing, the ultimate therapeutic potential of
MSCs appears to be limited because of poor engraftment
efficiency and cell retention at the wound site [27].
Moreover, the lack of sufficient MSC engraftment at
sites of injury is cited as a major limiting factor of
current MSC-based therapies [28]. Alternative methods
that increase the delivery or survival (or both) of MSCs
at the wound site are henceforth desirable. Kim et al.
[29] employed a three-dimensional collagen allograft
model, which is most similar to the skin dermis struc-
ture, to apply rat MSCs to wounds. This resulted in in-
creased neovascularization, accelerated healing, and,
interestingly, increased early expression of MMP-9,
which is thought to play a critical role in degrading
ECM to liberate VEGF and facilitate the initial steps of
angiogenesis. MMP-9 has also been reported to stimu-
late the production and secretion of VEGF in retinal pig-
ment epithelial cells [30]. Huang et al. [31] alternatively
used microsphere-based engineered skin containing
murine bone marrow-derived MSCs loaded with epider-
mal growth factor (EGF) and evaluated its effect on
murine wound healing. In these studies, a higher rate of
wound repair was found with thicker granulation tissue,
increased vasculature, and increased regeneration of
sweat gland-like structures compared with engineered
skin not loaded with EGF. This novel delivery system
highlights the therapeutic potential of adding EGF to
MSC delivery templates.
Investigators have also explored ways to increase MSC
mobilization and migration into cutaneous wounds. A
study examining the role of CXCL12/CXCR4 signaling
in the migration of murine bone marrow-derived MSCs
determined that the expression of CXCL12 (also known
as stromal derived factor-1) and CXCR4 was significantly
elevated in murine wounds treated with bone marrow-
derived MSCs [32]. Perhaps more importantly, an antag-
onist of CXCR4 inhibited the directional migration of
bone marrow MSCs in vitro, thus preventing MSCs
from participating in wound repair. These results coin-
cided with those of other studies, which found that
CXCL12 induced migration of MSCs following binding
to its cognate receptor, CXCR4 [33], and point to the
CXCL12/CXCR4 axis as a target for novel therapeuticstrategies. Similar migratory findings were observed in a
study by Roubelakis et al. [34], who reported that
platelet-rich plasma, a rich source of growth factors, sig-
nificantly increased the migration ability of human am-
niotic fluid MSCs and accelerated the healing process.
Using Mallotus philippinensis bark (EMPB) extract, Fur-
umoto et al. [35] likewise demonstrated an enhancement
of murine MSC migration, both into the blood circula-
tion and to the wound site. Application of EMPB, the
main activity of which is mediated by cinnamtannin B-1,
further resulted in improved wound healing and signifi-
cant increases in capillary number, suggesting a pro-
angiogenic role.
Prolonging the survival of MSCs in wounds would also
be expected to improve healing outcomes. Murine MSCs
seeded in a biomimetic hydrogel based on the carbohy-
drate pullulan, an alpha-(1–4)- and alpha-(1–6)-glucan
produced by the fungus Aureobasidium pullulans, was
seen to act as an antioxidant scaffold that improved
MSC survival by potentially protecting MSCs from high
levels of free radicals (which can impair MSC survival)
[36]. This finding agrees with the aforementioned idea
that detoxification of free radicals at wound sites pro-
motes proper wound healing [18].
Enhanced immunomodulation
Enhancing the immunomodulatory abilities of MSCs
would theoretically lead to better resolution of wound
inflammation. A study by Zhang et al. [37] found that
macrophages co-cultured with human gingival tissue
MSCs acquired the anti-inflammatory M2 phenotype,
demonstrated by increased expression of CD206 (a well-
accepted marker for the M2 macrophage) [38–40], a
high level of the anti-inflammatory cytokine IL-10, and a
low level of the pro-inflammatory cytokine TNF-α. Im-
portantly, injection of the gingival MSCs also resulted in
attenuated local inflammation, increased angiogenesis,
and significantly accelerated murine wound closure, sug-
gesting that gingival MSCs can promote cutaneous
wound repair by eliciting the polarization of macro-
phages toward an M2 phenotype. These results corrob-
orate the findings of other studies showing that M2
macrophages, also known as “wound-healing macro-
phages”, produce mediators essential for tissue remodel-
ing and the resolution of inflammation, thus promoting
wound repair [38, 41].
Another study evaluated the relationship between
microRNA and MSCs in wound healing [16]. Micro-
RNAs negatively regulate gene expression, and miRNA-
146a has specifically been reported to negatively regulate
the innate immune response. Evidence for a role of
miRNA-146a in wounds was seen in a diabetic murine
wound-healing model revealing significantly reduced
miRNA-146a expression levels and a dramatic increase
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with murine bone marrow MSCs resulted in improved
wound closure, significantly increased miRNA-146a ex-
pression, and downregulation of the pro-inflammatory
genes. These results suggest that modulation of miRNA-
146a levels by MSC treatment can decrease inflamma-
tion and enhance wound closure; miRNA-146a may also
be a future therapeutic target for MSC-based wound
therapies [16].
Further insight into the immunomodulatory capacity
of MSCs was provided by Qi et al., who found that
human bone marrow MSC-derived TNF-α-stimulated
protein 6 (TSG-6) was shown to suppress macrophage
TNF-α release, indirectly contributing to accelerated
murine wound healing [42]. These results were con-
firmed by the fact that TSG-6-silenced MSCs failed
to suppress macrophage-derived TNF-α release. Thus,
MSCs may contribute to resolution of inflammation,
and consequently promote wound healing, by inhibit-
ing release of the pro-inflammatory cytokine TNF-α.
MSC-derived TSG-6 may have a role in the develop-
ment of MSC-based wound therapies.
A mechanism by which MSCs exert immunomodu-
latory effects has been proposed by Waterman et al.,
who reported that stimulation of Toll-like receptor
(TLR)3 of human MSCs resulted in polarization to-
ward an immunosuppressive phenotype (MSC2)
needed for anti-inflammatory responses and tissue
healing [43]. Investigators also noted that stimulation
of TLR4 of MSCs contrastingly resulted in
polarization toward a pro-inflammatory phenotype
(MSC1) theorized to be important for early response
to tissue injury. It was therefore suggested that the
default MSC phenotype is immunosuppressive (to
prevent detrimental effects from a pro-inflammatory
one) and that MSCs can become pro-inflammatory to
promote early tissue repair. The role of TLR3 and
TLR4 stimulation in the immunomodulatory capabil-
ities of MSCs henceforth deserves further investiga-
tion, and studies examining this mechanism in
cutaneous wound healing may provide avenues for
MSC-based wound treatments.
Enhancement of angiogenesis
The pro-angiogenic role of MSCs has been well dem-
onstrated by multiple studies. Efforts to maximize this
capacity would be expected to increase the beneficial
role of MSCs on wound healing. Employing a bio-
mimetic hydrogel scaffold to deliver murine bone
marrow-derived MSCs into murine wounds, Rustad
et al. noted that MSCs cultured within the hydrogels
significantly increased VEGF levels, brought about a
faster rate of wound healing, resulting in more im-
proved skin architecture (with greater return of hairfollicles and sebaceous glands) compared with local
injection of MSCs [44]. Additionally, investigators ob-
served a moderate increase in microvessel number in
wounds treated with injected MSCs, but noted that
neovascularization was further augmented when
MSCs were delivered within the hydrogel scaffold.
Interestingly, levels of MMP-9, which was previously
mentioned to have a potential pro-angiogenic role,
were also significantly higher in wounds treated with
MSC-seeded scaffolds. In a separate study, Kim et al.
[45] demonstrated that low-level laser therapy (LLLT)
amplified the angiogenic ability of canine adipose-
derived MSCs. This was demonstrated by significantly
increased numbers of vasculature structures and
greater levels of MSC-derived VEGF and bFGF in
murine wounds treated with MSCs and LLLT com-
pared with wounds treated solely with MSCs. The
group treated with MSCs and LLLT also showed a
significantly smaller wound area, increased numbers
of hair follicles and sebaceous glands, and a decreased
percentage of caspase 3-positive MSCs (with a corre-
sponding increase in the number of MSCs), suggest-
ing a pro-survival, anti-apoptotic role. LLLT may
therefore enhance efficacy and survival of MSCs.
In another study, Tian et al. demonstrated that
14S,21R-dihydroxydocosa-4Z,7Z,10Z,12E,16Z,19Z-hex-
aenoic acid (14S,21R-diHDHA) administration induced
VEGF secretion by murine MSCs [46]. The 14S,21R-
diHDHA is a novel endogenous lipid mediator derived
from docosahexaenoic acid that has recently been shown
to be capable of promoting wound healing and angio-
genesis [47]. Together, 14S,21R-diHDHA and MSCs ap-
peared to act synergistically to promote wound
angiogenesis [46]. The 14S,21R-diHDHA also enhanced
the paracrine function of MSCs, leading to significantly
increased murine wound healing, accelerated re-
epithelialization, and promoted granulation tissue and
vasculature formation. Notably, skin wounds of diabetic
mice exhibited decreased formation of 14S,21R-
diHDHA; thus, 14S,21R-diHDHA may serve as a basis
for the development of treatment strategies for chronic
wounds [46].
Genetic modification of MSCs has also been ex-
plored. A study by Song et al. [48] found that intro-
duction of v-myc into human adipose-derived MSCs
using a lentiviral gene transfer system resulted in in-
creased MSC secretion of VEGF and increased vessel
formation. Investigators also took advantage of Akt1,
the expression of which increases MSC survival and
tissue repair ability [49]. Constitutively active phos-
phorylation in Akt1 further increased VEGF secretion
by v-myc MSCs and also caused accelerated murine
wound closure, decreased wound inflammation, and
improved epidermis formation [48].
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Several studies have shown that hypoxia can enhance
the efficacy of MSCs in regard to cutaneous wound heal-
ing. Using human amniotic fluid MSCs in a murine
wound-healing model, Jun et al. [50] found that MSCs
cultured in hypoxic conditions, compared with MSCs
cultured in normoxic conditions, had increased viability
and proliferation as well as increased expression of
VEGF. These MSCs also increased the viability and mi-
gration rate of human dermal fibroblasts, increased ex-
pression of ECM molecules (such as type III collagen,
fibronectin, and elastin), and accelerated wound closure.
Similar results were reported by Lee et al. [51], Kong
et al. [21], and Chen et al. [52], who evaluated the effect
of hypoxia on human adipose-derived MSCs, human
placenta-derived MSCs, and human bone marrow-
derived MSCs, respectively. Thus, hypoxia may have
great therapeutic potential in terms of enhancing the
ability of MSCs to promote proper wound healing and
regenerative skin repair.
Conclusions
The beneficial effect of MSCs on cutaneous wound heal-
ing has been well established. Through paracrine inter-
actions, MSCs increase wound closure rates, promote
angiogenesis, decrease wound inflammation, regulate
ECM healing events, and enhance regeneration of
proper skin structure and function. Recent studies have
evaluated novel methods to increase the therapeutic cap-
ability of MSCs. These measures have been shown to
increase MSC migration and survival, enhance immuno-
modulation, promote angiogenic capacity, and improve
overall efficacy. These results show promise for the fur-
ther development of MSC-based therapeutic strategies.
Future studies can further establish this research and
provide insight into how these findings can be applied in
the clinical arena. More work is also needed to deter-
mine the ideal source of MSCs, taking into account
therapeutic efficacy as well as availability, ethical issues,
and necessary procedures.
The therapeutic effects discussed in this review also
support a potential role for MSCs in recognized clinical
wound treatment models. For example, the wound bed
preparation model published by Sibbald et al. recognizes
prolonged inflammation as a principal component of
local wound care that requires clinical optimization [53].
This model discusses the fact that inflammation contrib-
utes to total wound pain and is a driving factor in the
persistence of chronic wounds (diabetic foot ulcers,
pressure ulcers, venous ulcers, and so on), which repre-
sent a substantial burden on a patient’s activities of daily
living as well as health-care systems worldwide. Because
of their immunomodulatory and angiogenic properties,
MSCs could be inserted into this model. A therapeuticstrategy employing MSCs could be added as a biologic
agent or advanced therapy option (or both) used specif-
ically to decrease inflammation, optimize wound bed
preparation, and promote cutaneous healing.
Abbreviations
14S,21R-diHDHA: 14S,21R-dihydroxydocosa-4Z,7Z,10Z,12E,16Z,19Z-hexaenoic
acid; bFGF: basic fibroblast growth factor; CD: cluster of differentiation;
ECM: extracellular matrix; EGF: epidermal growth factor; EMPB: Mallotus
philippinensis bark; GPx: glutathione peroxidase; ICAM1: intercellular adhesion
molecule 1; IL: interleukin; LLLT: low-level laser therapy; MMP: matrix
metalloproteinase; MSC: mesenchymal stem cell/multipotential mesenchymal
stromal cell; TGF-β: transforming growth factor-beta; TLR: toll-like receptor;
TNF-α: tumor necrosis factor-alpha; TSG-6: tumor necrosis factor-alpha-
stimulated protein 6; VEGF: vascular endothelial growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DEL performed the literature search, gathered the information, critically
evaluated the findings, and wrote the initial manuscript. NA participated in
critical discussion and interpretation of the findings in published literature.
DKA conceived of the study, participated in its design, assisted in the
drafting of the manuscript at various stages, and edited and finalized it to
submit it to the journal. All authors read and approved the final manuscript.
Acknowledgments
This work was supported by research grants R01HL104516, R01HL112597,
R01HL116042, and R01HL128063 to DKA from the Office of the Director,
National Institutes of Health (NIH), and the National Heart, Lung and Blood
Institute, NIH. The content of this review is solely the responsibility of the
authors and does not necessarily represent the official views of the NIH.
References
1. Ding D, Shyu W, Lin S. Mesenchymal stem cells. Cell Transpl. 2011;20:5–14.
2. Lee SH, Jin SY, Song JS, Seo KK, Cho KH. Paracrine effects of adipose-
derived stem cells on keratinocytes and dermal fibroblasts. Ann
Dermatol. 2012;24:136–43.
3. Schlosser S, Dennler C, Schweizer R, Eberli D, Stein JV, Enzmann V, et al.
Paracrine effects of mesenchymal stem cells enhance vascular regeneration
in ischemic murine skin. Microvasc Res. 2012;83:267–75.
4. Walter MNM, Wright KT, Fuller HR, MacNeil S, Johnson WEB.
Mesenchymal stem cell-conditioned medium accelerates skin wound
healing: an in vitro study of fibroblast and keratinocyte scratch assays.
Exp Cell Res. 2010;316:1271–81.
5. Smith AN, Willis E, Chan VT, Muffley LA, Isik FF, Gibran NS, et al.
Mesenchymal stem cells induce dermal fibroblast responses to injury. Exp
Cell Res. 2010;316:48–54.
6. Jeon YK, Jang YH, Yoo DR, Kim SN, Lee SK, Nam MJ. Mesenchymal stem
cells’ interaction with skin: wound-healing effect on fibroblast cells and skin
tissue. Wound Rep Regen. 2010;18:655–61.
7. Maharlooei MK, Bagheri M, Solhjou Z, Jahromi BM, Akrami M, Rohani L, et al.
Adiposed tissue derived mesenchymal stem cell (AD-MSC) promotes skin
wound healing in diabetic rats. Diabetes Res Clin Prac. 2011;93:228–34.
8. Liu L, Yu Y, Hou Y, Chai J, Hongjie D, Chu W, et al. Human umbilical cord
mesenchymal stem cells transplantation promotes cutaneous wound
healing of severe burned rats. PLoS One. 2014;9:1–8.
9. Kato J, Kamiya H, Himeno T, Shibata T, Kondo M, Okawa T, et al.
Mesenchymal stem cells ameliorate impaired wound healing through
enhancing keratinocyte functions in diabetic foot ulcerations on the plantar
skin of rats. J Diabet Its Complic. 2014;28:588–95.
10. Rodriguez-Menocal L, Shareef S, Salgado M, Shabbir A, Van Badiavas E. Role
of whole bone marrow, whole bone marrow cultured cells, and
mesenchymal stem cells in chronic wound healing. Stem Cell Res Ther.
2015;6:1–11.
11. Khong SML, Duscher D, Januszyk M, Than PA, Maan Z, Gurtner GC.
Single cell transcriptomic analysis of human fetal bone marrow-derived
Lee et al. Stem Cell Research & Therapy  (2016) 7:37 Page 8 of 8mesenchymal stem cells in wound healing. Plast Reconstr Surg. 2015;
135:123–4.
12. Nie C, Yang D, Xu J, Si Z, Jin X, Zhang J. Locally administered adipose-
derived stem cells accelerate wound healing through differentiation and
vasculogenesis. Cell Transpl. 2011;20:205–16.
13. Kim S, Zhang H, Guo L, Kim J, Kim MH. Amniotic mesenchymal stem cells
enhance wound healing in diabetic NOD/SCID mice through high
angiogenic and engraftment capabilities. PLoS One. 2012;7:1–11.
14. Cao Y, Sun Z, Liao L, Meng Y, Han Q, Zhao RC. Human adipose tissue-
derived stem cells differentiate into endothelial cells in vitro and improve
postnatal neovascularization in vivo. Biochem Biophys Res Commun. 2005;
332:370–9.
15. Lu F, Mizuno H, Uysal CA, Cai X, Ogawa R, Hyakusoku H. Improved viability
of random pattern skin flaps through the use of adipose-derived stem cells.
Plast Reconstr Surg. 2008;121:50–8.
16. Xu J, Wu W, Zhang L, Dorset-Martin W, Morris MW, Mitchell ME, et al. The
role of microRNA-146a in the pathogenesis of the diabetic wound-healing
impairment: correction with mesenchymal stem cell treatment. Diabet.
2012;61:2906–12.
17. Couture P, Paradis-Massie J, Oualha-Morin N, Thibault G. Adhesion and
transcellular migration of neutrophils and B lymphocytes on fibroblasts. Exp
Cell Res. 2009;315:2192–206.
18. Schafer M, Werner S. Oxidative stress in normal and impaired wound repair.
Pharmacol Res. 2008;58:165–71.
19. Ojeh NO, Navsaria HA. An in vitro skin model to study the effect of
mesenchymal stem cells in wound healing and epidermal regeneration. J
Biomed Mater Res Part A. 2013;102:2785–92.
20. Luo G, Cheng W, He W, Wang X, Tan J, Fitzgerald M, et al. Promotion of
cutaneous wound healing by local application of mesenchymal stem cells
derived from human umbilical cord blood. Wound Rep Regen. 2010;18:506–13.
21. Kong P, Xie X, Li F, Liu Y, Lu Y. Placenta mesenchymal stem cell accelerates
wound healing by enhancing angiogenesis in diabetic Goto-Kakizaki (GK)
rats. Biochem Biophys Res Commun. 2013;438:410–9.
22. Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, et al. Human
Wharton’s jelly mesenchymal stem cells promote skin wound healing
through paracrine signaling. Stem Cell Res Ther. 2014;5:1–13.
23. Azari O, Babaei H, Derakhshanfar A, Nematollahi-Mahani SN, Poursahebi R,
Moshrefi M. Effects of transplanted mesenchymal stem cells isolated from
Wharton’s jelly of caprine umbilical cord on cutaneous wound healing;
histopathological evaluation. Vet Res Commun. 2011;35:211–22.
24. Natesan S, Wrice NL, Baer DG, Christy RJ. Debrided skin as a source of
autologous stem cells for wound repair. Stem Cells. 2011;29:1219–30.
25. Hsieh J, Wang H, Chang S, Liao K, Lee I, Lin W, et al. Mesenchymal stem
cells from human umbilical cord express preferentially secreted factors
related to neuroprotection, neurogenesis, and angiogenesis. PLoS One.
2013;8:1–11.
26. Liu X, Wang Z, Wang R, Zhao F, Shi P, Jiang Y, et al. Direct comparison of
the potency of human mesenchymal stem cells derived from amnion
tissue, bone marrow and adipose tissue at inducing dermal fibroblast
responses to cutaneous wounds. Int J Mol Med. 2013;31:407–15.
27. Wagner J, Kean T, Young R, Dennis JE, Caplan AI. Optimizing mesenchymal
stem cell-based therapeutics. Curr Opin Biotech. 2009;20:531–6.
28. Chen JS, Wong VW, Gurtner GC. Therapeutic potential of bone marrow-
derived mesenchymal stem cells for cutaneous wound healing. Front
Immunol. 2012;3:1–9.
29. Kim CH, Lee JH, Won JH, Cho MK. Mesenchymal stem cells improve wound
healing in vivo via early activation of matrix metalloproteinase-9 and
vascular endothelial growth factor. J Korean Med Sci. 2011;26:726–33.
30. Holborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L, Bringmann
A. Positive feedback regulation between MMP-9 and VEGF in human RPE
cells. Invest Ophthalmol Vis Sci. 2007;48:4360–7.
31. Huang S, Lu G, Wu Y, Jirigala E, Xu Y, Ma K, et al. Mesenchymal stem cells
delivered in a microsphere-based engineered skin contribute to cutaneous
wound healing and sweat gland repair. J Dermatol Sci. 2012;66:29–36.
32. Hu C, Yong X, Li C, Lu M, Liu D, Chen L, et al. CXCL12/CXCR4 axis promotes
mesenchymal stem cell mobilization to burn wounds and contributes to
wound repair. J Surg Res. 2013;183:427–34.
33. Ryu CH, Park SA, Kim SM, Lim JY, Jeong CH, Jun JA, et al. Migration of
human umbilical cord blood mesenchymal stem cells mediated by stromal
cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction
pathways. Biochem Biophys Res Commun. 2010;398:105–10.34. Roubelakis MG, Trohatou O, Roubelakis A, Mili E, Kalaitzopoulos I,
Papazoglou G, et al. Platelet-rich plasma (PRP) promotes fetal mesenchymal
stem-stromal cell migration and wound healing process. Stem Cell Rev Rep.
2014;10:417–28.
35. Furumoto T, Ozawa N, Inami Y, Toyoshima M, Fujita K, Zaiki K, et al. Mallotus
philippinensis bark extracts promote preferential migration of mesenchymal
stem cells and improve wound healing in mice. Phytomed. 2014;21:247–53.
36. Wong VW, Rustad KC, Glotzbach JP, Sorkin M, Inayathullah M, Major MR,
et al. Pullulan hydrogels improve mesenchymal stem cell delivery into high-
oxidative-stress wounds. Macromol Biosci. 2011;11:1458–66.
37. Zhang Q, Su W, Shi-Hong S, Wilder-Smith P, Xiang AP, Wong A, et al.
Human gingiva-derived mesenchymal stem cells elicit polarization of
M2 macrophages and enhance cutaneous wound healing. Stem Cells.
2010;28:1856–68.
38. Fairweather D, Cihakova D. Alternatively activated macrophages in infection
and autoimmunity. J Autoimmun. 2009;33:222–30.
39. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an
immunologic functional perspective. Annu Rev Immunol. 2009;27:451–83.
40. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel
type of alternatively activated macrophages. Exp Hematol. 2009;37:1445–53.
41. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJC, John S, Taams LS.
CD4 + CD25 + Foxp3+ regulatory T cells induce alternative activation of human
monocytes/macrophages. Proc Natl Acad Sci U S A. 2007;104:19446–51.
42. Qi Y, Jiang D, Sindrilaru A, Stegemann A, Schatz S, Treiber N, et al. TSG-6
released from intradermally injected mesenchymal stem cells accelerates
wound healing and reduces tissue fibrosis in murine full-thickness skin
wounds. J Invest Derm. 2014;134:526–37.
43. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new
mesenchymal stem cell (MSC) paradigm: polarization into a pro-
inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One.
2010;5:1–14.
44. Rustad KC, Wong VW, Sorkin M, Glotzbach JP, Major MR, Rajadas J, et al.
Enhancement of mesenchymal stem cell angiogenic capacity and stemness
by a biomimetic hydrogel scaffold. Biomaterials. 2012;33:80–90.
45. Kim H, Choi K, Kweon O, Kim WH. Enhanced wound healing effect of
canine adipose-derived mesenchymal stem cells with low-level laser
therapy in athymic mice. J Dermatol Sci. 2012;68:149–56.
46. Tian H, Lu Y, Shah SP, Hong S. 14S,21R-Dihydroxydocosahexaenoic acid
remedies impaired healing and mesenchymal stem cell functions in
diabetic wounds. J Biol Chem. 2011;286:4443–53.
47. Lu Y, Tian H, Hong S. Novel 14,21-dihydroxy-docosahexaenoic acids:
structures, formation pathways, and enhancement of wound healing. J
Lipid Res. 2010;51:923–32.
48. Song S, Lee M, Lee J, Jeong H, Kim H, Kim W, et al. Genetic modification of
human adipose-derived stem cells for promoting wound healing. J
Dermatol Sci. 2012;66:98–107.
49. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, et al.
Mesenchymal stem cells modified with Akt prevent remodeling and restore
performance of infracted hearts. Nat Med. 2003;9:1195–201.
50. Jun EK, Zhang Q, Yoon BS, Moon J, Lee G, Park G, et al. Hypoxic
conditioned medium from human amniotic fluid-derived mesenchymal
stem cells accelerates skin wound healing through TGF-β/SMAD2 and PI3K/
Akt pathways. Int J Mol Sci. 2014;15:605–28.
51. Lee EY, Xia Y, Kim W, Kim MH, Kim TH, Kim KJ, et al. Hypoxia-enhanced wound-
healing function of adipose-derived stem cells: increase in stem cell proliferation
and up-regulation of VEGF and bFGF. Wound Rep Regen. 2009;17:540–7.
52. Chen L, Xu Y, Zhao J, Zhang Z, Yang R, Xie J, et al. Conditioned medium
from hypoxic bone marrow-derived mesenchymal stem cells enhances
wound healing in mice. PLoS One. 2014;9:1–12.
53. Sibbald RG, Goodman L, Woo KY, Krasner DL, Smart H, Tariq G, et al. Special
considerations in wound bed preparation 2011: an update. Adv Skin Wound
Care. 2011;24:415–36.
